LUPIN informs about press release

23 Jun 2023 Evaluate
LUPIN has informed that it enclosed a Press release regarding launch of Rufinamide Oral Suspension, 40 mg/mL to market a generic equivalent of Banzel Oral Suspension, 40 mg/mL of Eisai Inc. This is disclosure pursuant to Regulation 30 of the Listing Regulations.

The above information is a part of company’s filings submitted to BSE.

Peers
Company Name CMP
ICICINXT50 71.10
EMAMILTD7 423.00
TGV Securities
Arihant Mangal Scheme
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×